GenoSplice

“Acquired resistance to endocrine treatments is associated to tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.” Cottu PH, Bieche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Severly JL, Read more…

“Antagonistic functions of LMNA isoforms in energy expenditure and lifespan.” Lopez-Mejia IC, de Toledo M, Chavey C, Lapasset L, Cavelier P, Lopez-Herrera C, Chebli K, Fort P, Beranger G, Fajas L, Amri EZ, Casas F, Tazi J. EMBO Rep., 2014 Mar 17. Pubmed

“Sudemycin E influences alternative splicing and changes chromatin modifications.” Convertini P, Shen M, Potter PM, Palacios G, Lagisetti C, de la Grange P, Horbinski C, Fondufe-Mittendorf YN, Webb TR, Stamm S., Nucleic Acids Res. 2014 Mar 11. Pubmed

“A Gene Expression and Pre-mRNA Splicing Signature That Marks the Adenoma-Adenocarcinoma Progression in Colorectal Cancer” Pesson M, Volant A, Uguen A, Trillet K, De La Grange P, Aubry M, Daoulas M, Robaszkiewicz M, Le Gac G, Morel A, Simon B, Corcos L., PLoS One. 2014 Feb 6. Pubmed

“A dedicated microarray for in-depth analysis of pre-mRNA splicing events: application to the study of genes involved in the response to targeted anticancer therapies” Pesson M, Eymin B, De La Grange P, Simon B, Corcos L., Mol. Cancer, 2014 Jan. Pubmed

“Valproic Acid Causes Proteasomal Degradation of DICER and Influences miRNA Expression” Zhang Z, Convertini P, Shen M, Xu X, Lemoine F, de la Grange P, Andres DA, Stamm S, PLoS One. 2013 Dec. Pubmed

The publication “BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells” is on the cover of Blood Journal.  

“CXXC5 (Retinoid-Inducible Nuclear Factor, RINF) is a Potential Therapeutic Target in High-Risk Human Acute Myeloid Leukemia.” Astori A, Fredly H, Aloysius TA, Bullinger L, Mas VM, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud O, Oncotarget, 2013 Aug. Pubmed

“BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.” Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera ME, Hervatin F, Sarda-Mantel L, Konopleva M, Andreeff Read more…